This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Laura L. Fisher, MD; R. Gordon Douglas, Jr, MD

JAMA. 1991;265(23):3130-3132.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The new decade has already witnessed significant developments in the subspecialty of infectious diseases.

The acquired immunodeficiency syndrome (AIDS) remains the focus of worldwide epidemiologic, basic science, and clinical research. Zidovudine is the only therapy for the human immunodeficiency virus (HIV) approved by the Food and Drug Administration, although other promising antiretroviral drugs are being evaluated in clinical trials.^1,2

The list of indications for zidovudine treatment has been extended to include asymptomatic persons infected with HIV with fewer than 500 CD4 cells per cubic millimeter of blood. Other studies have attempted to determine the appropriate dosage for zidovudine, ie, that which maximizes therapeutic benefit while minimizing accompanying bone marrow toxic effects.³ Based on recent AIDS Clinical Trials Group study findings, many clinicians have lowered the maintenance dosage regimen to 500 or 600 mg of zidovudine daily. No recommendations have been made for asymptomatic infected individuals with more than . . . [Full Text PDF of this Article]

Author Affiliations
The New York Hospital-Cornell Medical Center, New York, NY; Merck Sharp & Dohme International, Rahway, NJ

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?